Supreme Court Demands Transparency on Stem Cell Therapy Trials for Autism
The Supreme Court of India has intensified its oversight of medical practices concerning Autism Spectrum Disorder (ASD), directing the Centre to provide a comprehensive status report on clinical trials involving stem cell therapy. A bench comprising Justices JB Pardiwala and R Mahadevan has sought clarity on how the government intends to transition patients previously undergoing “unregulated” stem cell treatments into a formal, research-oriented framework.
Addressing a Regulatory Vacuum
In a landmark judgment delivered on January 30, the Supreme Court ruled that stem cell therapy for autism cannot be marketed or administered as a routine clinical service. The court clarified that such procedures must be restricted exclusively to approved and strictly monitored research or clinical trial settings.
Following that ruling, the bench has now expressed dissatisfaction with the lack of progress regarding the integration of existing patients into these regulated environments. Consequently, the Union government has been ordered to file a detailed compliance affidavit. This report must disclose whether the authorities have received any formal applications for clinical trials since the January verdict. Furthermore, the court has demanded a list of all applicant institutions, the dates of these submissions, and the current administrative status of each proposal.
Standard of Care vs. Experimental Research
The medical stance on stem cell therapy for autism remains clear: it is not recognized as a standard, approved treatment. According to the Ministry of Health and Family Welfare and the Indian Council of Medical Research (ICMR), stem cell procedures are only permitted for specific, approved medical conditions. Outside of this designated list, such therapies are considered strictly experimental.
The court’s scrutiny aligns with international standards, such as those upheld by the United States Food and Drug Administration (FDA). The FDA limits its approval for stem cell therapies to treatments for blood-related cancers and specific immune system disorders, consistently labeling all other applications as experimental. By demanding that the Centre explain its oversight, the Supreme Court is aiming to prevent private entities from bypassing safety protocols and offering unproven therapies to vulnerable populations.
Accountability for Clinics and Guardians
The judicial directive extends beyond the government to include the medical providers and the families involved. The bench has ordered the Parents Forum for Stem Cells in Autism and Cerebral Palsy, along with the various clinics currently administering these therapies, to submit evidence regarding their adherence to the January order.
These parties must now formally clarify whether they have taken any concrete steps to align their ongoing practices with established clinical trial guidelines. The court is seeking to determine if these private clinics have sought the necessary regulatory permissions to continue their operations within the legal framework, or if they have failed to comply with the court’s mandates.
This proactive stance by the judiciary reflects a growing concern over the commercial exploitation of medical uncertainties surrounding ASD. With the matter slated for further hearing on September 29, the government and medical institutions are under significant pressure to prove that they are prioritizing patient safety over profit-driven, unverified medical interventions.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
